Safety , Feasibility and Preliminary Efficacy of Remote Ischemic Conditioning in Patients With Aneurysmal Subarachnoid Hemorrhage After Aneurysm Clipping

Condition(s) studied

Investigational drug(s) / intervention(s)

Remote Ischemic Conditioning Treatment Instrument: Remote ischemic conditioning (RIC) was administered twice daily to the unilateral lower limb using a blood pressure cuff inflated to 200 mmHg for 7 consecutive days post-clipping

Guideline-based therapy: Guideline-based therapy

Study summary

This study was designed to evaluate the safety and efficacy of remote ischemic conditioning (RIC) in patients with aneurysmal subarachnoid hemorrhage (aSAH) following surgical clipping.

Aneurysmal subarachnoid hemorrhage is a life-threatening condition that occurs when a cerebral aneurysm ruptures, causing bleeding into the subarachnoid space. Surgical clipping of the aneurysm is a standard procedure used to stop the bleeding and prevent re-rupture, thereby stabilizing the patient's condition.

Remote ischemic conditioning (RIC) is a non-invasive treatment that involves using a blood pressure cuff to induce brief, temporary cycles of ischemia and reperfusion in a limb. Research suggests that this process may confer systemic protective effects, potentially improving recovery from brain injury or surgery. Although RIC has shown potential to improve outcomes in patients with other neurological conditions, its effect on patients with aSAH who undergo surgical clipping remains unclear.

This study will evaluate whether RIC can reduce complications, improve neurological function, and enhance overall recovery in these patients. The findings will help determine whether RIC should be incorporated into the standard treatment regimen for aSAH.

Eligibility

Primary outcome measure(s)

• Proportion of mRS (0-2) — 90±7 days post-enrollment in the study
  Modified Rankin Scale, mRS; min:0, max:6; A smaller score indicates a better prognosis.
• incidence rate of RIC adverse events — From enrollment to the end of RIC at 1 week
  RIC adverse events mainly include: limb pain, skin damage, deep vein thrombosis, transient hypertension, etc.

Trial sites (1)

More Beijing Tiantan Hospital trials in China

Other trials for the same condition